By Chor Sing Tan, Strategy Manager, Cytiva
Single-use bioprocess technology offers several advantages for manufacturing biopharmaceuticals, such as a greater diversity of systems to support bioprocessing unit operation (i.e., rocking and stirred tank bioreactor) and enabling transportation of process liquid and drug bulk substance between biomanufacturers’ production sites. Single-use systems (SUSs) are typically fabricated using polymer films containing materials such as polyethylene (PE), polypropylene (PP), or ethyl vinyl acetate (EVA). Composition of the polymer film has a strong influence on the construction, performance characteristics, and manufacturability of the SUS. The majority of polymer films used in SUSs in the market today are adopted from other applications, such as food packaging and blood bags. These films are usually limited to one specific bioprocessing application and are not well characterized in terms of biocompatibility data. Also, these films are typically supplemented with additives to prolong their usability and manufacturability. The presence of additives has resulted in adverse effects of polymer films on cell growth and metabolism.
Continue reading to learn about Fortem film development, an important investment by Cytiva. It helps meet the industry need for a fully characterized platform film across all bioprocessing applications with supply chain transparency as a focal point.